SCHEMBL24258510

SCHEMBL24258510

c1cc2cc(-c3ccc4c(c3)CNCCC4)ccc2[nH]1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.47
NISCH Q9Y2I1 1/20 0.43
CYP2D6 P10635 1/20 0.42
SLC6A2 P23975 1/20 0.42
SLC6A4 P31645 1/20 0.42
SLC6A3 Q01959 1/20 0.42
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA9 Q16790 1/20 0.41
CYP17A1 P05093 1/20 0.40
CYP11B1 P15538 1/20 0.40
CYP11B2 P19099 1/20 0.40
HDAC2 Q92769 1/20 0.39
ASIC3 Q9UHC3 1/20 0.39
PARP10 Q53GL7 1/20 0.39
PARP11 Q9NR21 1/20 0.39
PTGS2 P35354 1/20 0.38
PNMT P11086 3/20 0.37
IMPDH2 P12268 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25405473 0.85 ASIC3 (0.55) NPC1NISCHCYP2D6SLC6A2SLC6A4
SCHEMBL5912311 0.80 CYP2D6 (0.40) CYP2D6SLC6A2SLC6A4SLC6A3PNMT
SCHEMBL5850255 0.74 NPC1 (0.79) NPC1NISCHCA12CA1CA2
SCHEMBL24222564 0.72 ABCB1 (0.53) NPC1NISCHSLC6A2SLC6A4SLC6A3
SCHEMBL30481091 0.70 PNMT (0.44) ASIC3PNMTADRA2AADRA2BADRA2C
SCHEMBL6313377 0.70 PNMT (0.44) ASIC3PNMTADRA2AADRA2BADRA2C
SCHEMBL6308292 0.70 PNMT (0.44) ASIC3PNMTADRA2AADRA2BADRA2C
SCHEMBL10200729 0.69 NISCH (0.42) NPC1NISCHCYP2D6SLC6A2SLC6A4
SCHEMBL25452806 0.69 ADRA2A (0.54) NPC1NISCHCYP2D6SLC6A2SLC6A4
SCHEMBL18554694 0.69 ASIC3 (0.49) ASIC3PNMTADRA2AADRA2BADRA2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3464270-B1 HETEROCYCLIC INHIBITORS OF CBP/EP300 AND THEIR USE IN THE TREATMENT OF CANCER GENENTECH INC (US) 2022-02-23 EP disclosed